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Short Report: Complications
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Abstract
Aims To assess whether there is a relationship between delay in retinopathy screening after diagnosis of Type 2
diabetes and level of retinopathy detected.
Methods Patients were referred from 88 primary care practices to an English National Health Service diabetic eye
screening programme. Data for screened patients were extracted from the primary care databases using semi-automated
data collection algorithms supplemented by validation processes. The programme uses two-field mydriatic digital
photographs graded by a quality assured team.
Results Data were available for 8183 screened patients with diabetes newly diagnosed in 2005, 2006 or 2007. Only
163 with Type 1 diabetes were identified and were insufficient for analysis. Data were available for 8020 with newly
diagnosed Type 2 diabetes. Of these, 3569 were screened within 6 months, 2361 between 6 and 11 months, 1058
between 12 and 17 months, 366 between 18 and 23 months, 428 between 24 and 35 months, and 238 at 3 years or
more after diagnosis. There were 5416 (67.5%) graded with no retinopathy, 1629 (20.3%) with background retinopathy
in one eye, 753 (9.4%) with background retinopathy in both eyes and 222 (2.8%) had referable diabetic retinopathy.
There was a significant trend (P = 0.0004) relating time from diagnosis to screening detecting worsening retinopathy. Of
those screened within 6 months of diagnosis, 2.3% had referable retinopathy and, 3 years or more after diagnosis, 4.2%
had referable retinopathy.
Conclusions The rate of detection of referable diabetic retinopathy is elevated in those who were not screened promptly
after diagnosis of Type 2 diabetes.
Diabet. Med. 31, 439–442 (2014)
Introduction
There is a strong correlation between incidence of diabetic
retinopathy and duration of diabetes [1]. Detection of
referable diabetic retinopathy at a patient’s first screening
appointment raises the following questions:
1. Could this relate to the time course of development of
diabetes? Referable diabetic retinopathy around the time of
diagnosis is recognized in Type 2 diabetes [2]. We know
fromcloselymonitoredpopulations such as theWhitehall II
study [3] that blood glucose rises above normal only around
18 months before diagnosis of diabetes. In populations like
this who are regularly screened for diabetes, the prevalence
of diabetic retinopathy is low [4]. In those who present
symptomatically with diabetes, the onset of diabetes is
estimated [5,6] to be 4–7 years before diagnosis and the
prevalence of retinopathy is reported to be higher [2].
2. Is this attributable to the screening programme not being
informed in a timely fashion of the diagnosis? Diabetic eye
screening programmes are totally reliant on general
practices informing them of all newly diagnosed patients
and, as this is predominantly a manual process, errors and
omissions are sometimes made.
3. Is this because of the person with diabetes not attending the
screening appointment? Those on the screening register are
invited within 3 months of being added to the register and
then annually, but may choose not to take up the invitation,
or may wait for two or more years before doing so.
In order to determine whether delay in screening for
diabetic retinopathy as a result of any of the above factors
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might be clinically important, we determined the prevalence
of referable diabetic retinopathy at the first screening
episode by time after diagnosis in patients attending the
Gloucestershire Diabetic Eye Screening Programme
(GDESP).
Methods
Data for patients referred to the eye screening programme
were extracted from the primary care databases with
semi-automated data collection algorithms supplemented
by validation processes using procedures developed under
the General Practice to Diabetic Retinopathy Screening
(GP2DRS) project, which was initiated as a joint initiative
between the English National Health Service (NHS) Diabetic
Eye Screening Programme (DESP) and Connecting for
Health to automatically extract patient records from general
practices. Patients were referred from 88 primary care
practices and invited for screening at a local primary care
practice with mobile cameras. Digital retinal images of both
eyes were taken after pharmacological dilatation and graded
by the quality-assured grading team. People with diabetes in
this programme are routinely sent an invitation to phone to
book an appointment with the screening service within
3 months of the service being informed by the general
practice of the new person with diabetes and then once a
year, with one reminder being sent if they do not take up the
annual offer.
Data collected from the screening programme were anal-
ysed to examine the proportion with diabetic eye disease at
intervals from diagnosis of diabetes. In the English NHS
Diabetic Eye Screening Programme, all images are automat-
ically allocated a retinopathy (R) grade and a maculopathy
Table 1 Comparison between the retinopathy grading classification of the English NHS DESP and the ETDRS
English retinopathy classification (R levels—R0, R1, R2 or R3)
Outcome English Screening
Programme levels
ETDRS final
retinopathy severity
scale
ETDRS(final)
grade
Risk of progression
to proliferative
diabetic
retinopathy in
1 year
Re-screen in 12 months R0 (no retinopathy) No apparent
retinopathy
10, 14, 15
Re-screen in 12 months R1 (background retinopathy),
microaneurysm(s), retinal
haemorrhage(s), any exudate
Mild
non-proliferative
retinopathy
20–35 6.2%
Routine referral to
ophthalmologist
R2 (pre-proliferative retinopathy),
venous beading, venous
reduplication, intraretinal
microvascular abnormality, multiple
blot haemorrhages
Moderate
non-proliferative
retinopathy
43 11.3%
Moderately severe
non-proliferative
retinopathy
47 20.7%
Severe
non-proliferative
retinopathy
53 44.2–54.8%
Urgent referral to ophthalmologist R3 (proliferative) Proliferative diabetic
retinopathy
61 and
greater
Proliferative
diabetic
retinopathy has
developed
English maculopathy classification (M levels—M0 or M1)*
Outcome
Re-screen in 12 months M0 None of the features below
Routine referral to ophthalmologist M1 Exudate within 1 disc diameter of the centre of the fovea
Routine referral to ophthalmologist M1 Circinate or group of exudates within the macula
Routine referral to ophthalmologist M1 Any microaneurysm or haemorrhage within 1 disc
diameter of the centre of the fovea only if associated
with a best visual acuity of ≤ 6/12 (if no stereo)
Routine referral to ophthalmologist M1 Retinal thickening within 1 disc diameter of the centre
of the fovea (if stereo available)
*Retinopathy R level must be at least R1 to classify any M1.
ETDRS, Early Treatment Diabetic Retinopathy Study;
What’s new?
• This report is the first that has described a relationship
between rate of detection of referable diabetic retinop-
athy and delay in screening for diabetic retinopathy
after diagnosis of Type 2 diabetes.
• We would like to use this report as evidence to ask for a
new quality standard in UK diabetic eye screening
programmes. We suggest a target be set for proportion
screened within 2 years of being added to the screening
register.
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(M) grade on the basis of the absence, presence and severity
of features of diabetic retinopathy found during grading of
the retinal images. The criteria used for grading and
allocation of retinopathy and maculopathy levels in the
Gloucestershire Diabetic Eye Screening Programme, which
are those required by the English NHS Diabetic Eye
Screening Programme [7], and the relationship to the Early
Treatment Diabetic Retinopathy Study (ETDRS) severity
scale [8,9] are shown in Table 1.
Any diabetic retinopathy was defined as having a grade
other than R0M0 in at least one eye. Referable diabetic
retinopathy was defined by the presence of any moderate to
severe non-proliferative diabetic retinopathy (R2), prolifer-
ative diabetic retinopathy (R3) or maculopathy (M1) in
either eye. Patients with unassessable images were excluded
from the analyses here.
Results
Data were available for 8183 patients newly diagnosed with
diabetes between 2005 and 2007.
Only 163 with Type 1 diabetes were available, which was
an insufficient number to show any trends in the analysis,
and hence these subjects were excluded.
Data were available for 8020 subjects with newly diag-
nosed Type 2 diabetes (see Fig. 1 and Table 2).
Of these, 3569 were screened within 6 months, 2361 were
screened between 6 and 11 months, 1058 between 12 and
17 months, 366 between 18 and 23 months, 428 between 24
and 35 months and 238 at 3 years or more after diagnosis.
Overall, there were 5416 (67.5%) graded with no
retinopathy (R0M0) in both eyes, 1629 (20.3%) with
background non-referable retinopathy (R1M0) in one eye,
753 (9.4%) with background diabetic retinopathy (R1M0) in
both eyes and 222 (2.8%) with referable diabetic retinopathy
in one or both eyes.
There was a significant trend (P = 0.0004) relating time
from diagnosis to screening, with worsening diabetic reti-
nopathy.
Of those screened within 6 months of diagnosis, 2.3% had
referable diabetic retinopathy. In those screened 3 years or
more after diagnosis, 4.2% had referable diabetic retino-
pathy.
Discussion
Zoega et al. [10] described the relationship between
non-attendance for diabetic retinopathy screening and blind
registration in a small population of 22 people with diabetes
registered blind in Iceland.
We recently published [11] an audit that we undertook in a
large general practice in Gloucester, which demonstrated
that attendance for diabetic eye screening was inversely
associated with HbA1c (P < 0.0001), systolic and diastolic
blood pressure (P = 0.005), suggesting that those with the
poorest control of their diabetes and blood pressure were
least likely to attend.
Other factors that are known to affect attendance are:
1. Patient age—younger patients had a higher propensity for
non-attendance at diabetic retinopathy screening [12,13].
2. Socio-economic deprivation [14].
Table 2 Relationship between time from diagnosis to screening and diabetic retinopathy severity
Time from diagnosis of diabetes to screening
No retinopathy
(R0M0) in both
eyes
Background
retinopathy
(R1M0) in one
eye
Background
retinopathy
(R1M0) in both
eyes
Referable
diabetic
retinopathy
< 6 months 2449 68.6% 719 20.1% 320 9.0% 81 2.3%
6–11 months 1610 68.2% 463 19.6% 218 9.2% 70 3.0%
12–17 months 689 65.1% 231 21.8% 104 9.8% 34 3.2%
18–23 months 239 65.3% 80 21.9% 36 9.8% 11 3.0%
24–35 months 273 63.8% 93 21.7% 46 10.7% 16 3.7%
36–47 months 109 69.4% 28 17.8% 13 8.3% 7 4.5%
48–66 months 47 58.0% 15 18.5% 16 19.8% 3 3.7%
v2-test for trend, P = 0.0004.
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FIGURE 1 Proportion of subjects with referable diabetic retinopathy;
v2 for trend, P = 0.0004.
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3. Type of diabetes—attendance rates at diabetic retinopathy
screening were found to be lower in patients with Type 1
diabetes [13].
This current study has demonstrated that the rate of
detection of referable diabetic retinopathy is higher in those
who were not screened promptly after diagnosis of Type 2
diabetes. This study does not differentiate between whether
those who were screened later had more severe diabetic
retinopathy at diagnosis or whether the lateness in being
screened was related to the compliance issues that have
previously been published. It also does not differentiate
between people with diabetes who have good or poor control
of blood glucose, because English NHS Diabetic Eye
Screening Programmes do not routinely have access to
HbA1c data. It does, however, indicate that it would be
beneficial to screen people within the current National
Institute for Health and Clinical Excellence (NICE) [15]
Quality Standard of within 3 months of diagnosis.
It also suggests that a new Quality Standard should be
introduced in the English NHS Diabetic Eye Screening
Programme to minimize the number of people who have a
long delay in their first screening appointment and, in
particular, the number of people who have not taken up their
offer of screening within 3 years of diagnosis.
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